XORTX Therapeutics Inc ( (TSE:XRTX) ) has issued an announcement.
On April 28, 2025, XORTX Therapeutics Inc. announced the grant of a European patent for its ‘Xanthine Oxidase Inhibitor Formulations.’ This patent strengthens the company’s intellectual property portfolio in the EU and supports its programs for gout and autosomal dominant polycystic kidney disease (ADPKD). The patent covers compositions and methods for treating conditions related to high uric acid levels, such as gout and kidney diseases, and provides XORTX with enhanced commercialization and partnering opportunities in Europe. The issuance of this patent is expected to bolster XORTX’s position in the pharmaceutical industry, particularly in addressing unmet medical needs in the treatment of hyperuricemia-related conditions.
Spark’s Take on TSE:XRTX Stock
According to Spark, TipRanks’ AI Analyst, TSE:XRTX is a Underperform.
The overall stock score for XORTX Therapeutics Inc is low, driven primarily by its poor financial performance with no revenue and consistent losses. The technical analysis indicates bearish market conditions, further weighing down the score. Valuation metrics also reflect a negative assessment as the P/E ratio is negative, with no dividends to offset the lack of earnings. The combination of these factors suggests significant challenges ahead for the company.
To see Spark’s full report on TSE:XRTX stock, click here.
More about XORTX Therapeutics Inc
XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing innovative therapies for treating gout and progressive kidney disease. The company is advancing products targeting aberrant purine metabolism and xanthine oxidase to decrease or inhibit uric acid production. XORTX’s pipeline includes the XRx-026 program for gout, XRx-008 for autosomal dominant polycystic kidney disease (ADPKD), and XRx-101 for acute kidney and organ injury associated with respiratory virus infections.
YTD Price Performance: -10.84%
Average Trading Volume: 7,157
Technical Sentiment Signal: Buy
Current Market Cap: C$5.61M
For detailed information about XRTX stock, go to TipRanks’ Stock Analysis page.